bemcentinib (BGB324)

News alerts, weekly reports and conference planners

Company:

BerGenBio, Rigel

Drug class:

AXL inhibitor

Related drugs:

AXL positive	Non Small Cell Lung Cancer	AXL positive	Non Small Cell Lung Cancer	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + BGB324 Sensitive: B - Late Trials pembrolizumab + BGB324 Sensitive : B	pembrolizumab + BGB324 Sensitive: B - Late Trials pembrolizumab + BGB324 Sensitive : B
AXL expression	Non Small Cell Lung Cancer	AXL expression	Non Small Cell Lung Cancer	pembrolizumab + BGB324 Sensitive: C2 – Inclusion Criteria pembrolizumab + BGB324 Sensitive : C2	pembrolizumab + BGB324 Sensitive: C2 – Inclusion Criteria pembrolizumab + BGB324 Sensitive : C2
SLFN11 expression	Myelodysplastic Syndrome	SLFN11 expression	Myelodysplastic Syndrome	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
ANG elevation	Myelodysplastic Syndrome	ANG elevation	Myelodysplastic Syndrome	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
AXL elevation	Myelodysplastic Syndrome	AXL elevation	Myelodysplastic Syndrome	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
SLFN11 expression	Acute Myelogenous Leukemia	SLFN11 expression	Acute Myelogenous Leukemia	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
ANG elevation	Acute Myelogenous Leukemia	ANG elevation	Acute Myelogenous Leukemia	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
AXL elevation	Acute Myelogenous Leukemia	AXL elevation	Acute Myelogenous Leukemia	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab + BGB324 Sensitive: C3 – Early Trials pembrolizumab + BGB324 Sensitive : C3	pembrolizumab + BGB324 Sensitive: C3 – Early Trials pembrolizumab + BGB324 Sensitive : C3
KRAS mutation + PD-L1 negative	Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation + PD-L1 negative	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab + BGB324 Sensitive: C3 – Early Trials pembrolizumab + BGB324 Sensitive : C3	pembrolizumab + BGB324 Sensitive: C3 – Early Trials pembrolizumab + BGB324 Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D
ALK-ROS1 fusion	Non Small Cell Lung Cancer	ALK-ROS1 fusion	Non Small Cell Lung Cancer	crizotinib + BGB324 Sensitive: D – Preclinical crizotinib + BGB324 Sensitive : D	crizotinib + BGB324 Sensitive: D – Preclinical crizotinib + BGB324 Sensitive : D
AXL overexpression	Ovarian Cancer	AXL overexpression	Ovarian Cancer	VS-6766 + BGB324 Sensitive: D – Preclinical VS-6766 + BGB324 Sensitive : D	VS-6766 + BGB324 Sensitive: D – Preclinical VS-6766 + BGB324 Sensitive : D
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	VS-6766 + BGB324 Sensitive: D – Preclinical VS-6766 + BGB324 Sensitive : D	VS-6766 + BGB324 Sensitive: D – Preclinical VS-6766 + BGB324 Sensitive : D
BRAF mutation	Melanoma	BRAF mutation	Melanoma	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D
FGFR2-AFF4 fusion	Cholangiocarcinoma	FGFR2-AFF4 fusion	Cholangiocarcinoma	pemigatinib + BGB324 Sensitive: D – Preclinical pemigatinib + BGB324 Sensitive : D	pemigatinib + BGB324 Sensitive: D – Preclinical pemigatinib + BGB324 Sensitive : D
FGFR2-AFF4 fusion	Cholangiocarcinoma	FGFR2-AFF4 fusion	Cholangiocarcinoma	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D
KRAS mutation + STK11 mutation + AXL expression	Lung Adenocarcinoma	KRAS mutation + STK11 mutation + AXL expression	Lung Adenocarcinoma	pembrolizumab + BGB324 Sensitive: D – Preclinical pembrolizumab + BGB324 Sensitive : D	pembrolizumab + BGB324 Sensitive: D – Preclinical pembrolizumab + BGB324 Sensitive : D
KRAS mutation + STK11 mutation	Lung Adenocarcinoma	KRAS mutation + STK11 mutation	Lung Adenocarcinoma	pembrolizumab + BGB324 Sensitive: D – Preclinical pembrolizumab + BGB324 Sensitive : D	pembrolizumab + BGB324 Sensitive: D – Preclinical pembrolizumab + BGB324 Sensitive : D
STK11 mutation + KRAS mutation + TP53 deletion	Non Small Cell Lung Cancer	STK11 mutation + KRAS mutation + TP53 deletion	Non Small Cell Lung Cancer	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D
AXL overexpression	Melanoma	AXL overexpression	Melanoma	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D
AXL overexpression	Melanoma	AXL overexpression	Melanoma	vemurafenib + BGB324 Sensitive: D – Preclinical vemurafenib + BGB324 Sensitive : D	vemurafenib + BGB324 Sensitive: D – Preclinical vemurafenib + BGB324 Sensitive : D
OPCML underexpression + AXL overexpression	Hepatocellular Cancer	OPCML underexpression + AXL overexpression	Hepatocellular Cancer	BGB324 Resistant: D – Preclinical BGB324 Resistant : D	BGB324 Resistant: D – Preclinical BGB324 Resistant : D

bemcentinib (BGB324)

Associations
(26)

Associations
(26)

bemcentinib (BGB324)

Associations(26)

Associations(26)

Associations
(26)

Associations
(26)